Optimal scheduling to reduce morbidity of involved field radiotherapy with transplantation for lymphomas: a prospective Australasian Leukaemia and Lymphoma Group Study.

abstract：:Among the drugs used in conditioning regimens for stem cell transplantation, high-dose melphalan (HDM) plays an important role for both its strong myeloablative effect and for its favourable dose-response ratio. Here we report five cases of high frequency atrial fibrillation (AF) developing after HDM. Duration of the ...

journal_title：Bone marrow transplantation

authors： Olivieri A,Corvatta L,Montanari M,Brunori M,Offidani M,Ferretti GF,Centanni M,Leoni P

更新日期：1998-05-01 00:00:00

abstract：:The CXCR4-inhibitor plerixafor mobilizes hematopoietic stem cells amplifying the effects of granulocyte-CSF (G-CSF). Before approval plerixafor was used in a compassionate use program (CUP) for patients who failed a previous mobilization. In the German CUP 60 patients from 23 centers (median age 56.5 years (2-75)) wer...

journal_title：Bone marrow transplantation

authors： Hübel K,Fresen MM,Salwender H,Basara N,Beier R,Theurich S,Christopeit M,Bogner C,Galm O,Hartwig R,Heits F,Lordick F,Rösler W,Wehler D,Zander AR,Albert MH,Dressler S,Ebinger M,Frickhofen N,Hertenstein B,Kiehl M,L

更新日期：2011-08-01 00:00:00

abstract：:Rapid identification of a matched unrelated donor is essential for patients in need of hematopoietic SCT. We carried out a retrospective evaluation of 549 unrelated donor searches (UDSs), which were completed in 2005 for 23 German transplant centers. On the basis of the patient's HLA-DRB1 allele and DRB1-DQB1 haplotyp...

journal_title：Bone marrow transplantation

authors： Hirv K,Bloch K,Fischer M,Einsiedler B,Schrezenmeier H,Mytilineos J

更新日期：2009-10-01 00:00:00

abstract：:IL-10 plays an important role in the control of immune reactions during systemic infection. Here, IL-10 serum levels were investigated in patients after BMT. The IL-10 levels correlated with the clinical course of the patients and with serum levels of C-reactive protein (CRP) and neopterin (NP). A total of 26 patients...

journal_title：Bone marrow transplantation

authors： Hempel L,Körholz D,Nussbaum P,Bönig H,Burdach S,Zintl F

更新日期：1997-09-01 00:00:00

abstract：:Post-transplant lymphoproliferative disorders (PTLD) are morphologically/clinically heterogeneous. The main goal of this study was to define the histogenesis of PTLD (B-cell phenotype, EBV-related) in seven pediatric patients after allogeneic T-cell-depleted bone marrow transplantation. Immunohistochemical stains usin...

journal_title：Bone marrow transplantation

authors： Abed N,Casper JT,Camitta BM,Margolis D,Trost B,Orentas R,Chang CC

更新日期：2004-02-01 00:00:00

abstract：:To perform an optimal ex vivo bone marrow purge, it is necessary to concentrate the bone marrow progenitor cells and to eliminate both the red blood cells and the polymorphonuclear leucocytes. To achieve this goal which cannot be accomplished by using the Haemonetics model 30 alone, we used the Haemonetics model 30 an...

journal_title：Bone marrow transplantation

authors： Humblet Y,Lefebvre P,Jacques JL,Bosly A,Feyens AM,Sekhavat M,Agaliotis D,Symann M

更新日期：1988-01-01 00:00:00

abstract：:The kinetics of mobilization and optimal timing of peripheral blood progenitor cell (PBPC) collection were evaluated in 190 patients with multiple myeloma undergoing stem cell harvest after mobilization with cyclophosphamide, prednisone and G-CSF. There was a strong correlation between the WBC count and the number of ...

journal_title：Bone marrow transplantation

authors： Krieger MS,Schiller G,Berenson JR,Stewart K,Noga SJ,Ballester O,Tarantolo S,Stiff P,Kuhn D,Scherzo E,Sing A,Jacobs C,White JM,DiPersio J

更新日期：1999-07-01 00:00:00

abstract：:The toxicity of the conditioning regimen high-dose busulfan (BU) 16 mg/kg followed by cyclophosphamide (CY) 200 mg/kg has been analysed in 60 adult patients (mean age 36 +/- 9 years) with haematological malignancies, a third of whom had advanced disease, all received the graft from fully HLA-identical siblings. Signif...

journal_title：Bone marrow transplantation

authors： Bandini G,Belardinelli A,Rosti G,Calori E,Motta MR,Rizzi S,Benini C,Tura S

更新日期：1994-05-01 00:00:00

abstract：:Hematopoietic SCT is currently the only curative therapy for a range of benign inherited and acquired primary hematologic disorders in children, including BM failure syndromes and hemoglobinopathies. The preferred HLA-matched sibling donor is available for only about 25% of such children. However, there has been subst...

journal_title：Bone marrow transplantation

authors： Tolar J,Sodani P,Symons H

更新日期：2015-05-01 00:00:00

abstract：:Relapse is a serious complication following high-dose therapy and autologous bone marrow transplantation (ABMT) for malignant lymphoma (ML). Allogeneic transplantation (alloSCT) is a therapeutic option. However, it is associated with a high incidence of transplant-related organ toxicity and mortality. We recently repo...

journal_title：Bone marrow transplantation

authors： Nagler A,Slavin S,Varadi G,Naparstek E,Samuel S,Or R

更新日期：2000-05-01 00:00:00

abstract：:To augment graft cell dose, we evaluated the safety of the combined transplantation of two partially HLA-matched umbilical cord blood (UCB) units. Five patients with transfusion-dependent thalassemia, median age 11.1 years (range 10-13.1), received 2 UCB units after myeloablative conditioning. Cord blood units were a ...

journal_title：Bone marrow transplantation

authors： Jaing TH,Yang CP,Hung IJ,Chen SH,Sun CF,Chow R

更新日期：2007-08-01 00:00:00

abstract：:The efficacy of ciprofloxacin as antibacterial prophylaxis for allogeneic bone marrow transplantation has been well documented, and it virtually eliminated bacteremias caused by gram-negative pathogens in early reports. Ciprofloxacin was therefore incorporated into the prophylactic antibiotic regimen during allogeneic...

journal_title：Bone marrow transplantation

authors： Yeh SP,Hsueh EJ,Yu MS,Wu H,Wang YC

更新日期：1999-12-01 00:00:00

abstract：:A phase I/II trial evaluated early administration and dose escalation of interleukin (IL)-2 with granulocyte macrophage colony stimulating factor (GM-CSF) post-transplant. Following melphalan (200 mg/m(2)) and an autologous transplant, IL-2 was initiated (day 0) and continued for 4 weeks. GM-CSF (250 mcg/m(2)/day) beg...

journal_title：Bone marrow transplantation

authors： Meehan KR,Wu J,Bengtson E,Hill J,Ely P,Szczepiorkowski Z,Kendall M,Ernstoff MS

更新日期：2007-06-01 00:00:00

abstract：:We report the results of a retrospective analysis in 27 pediatric patients who received low-dose MTX as the second-line treatment for steroid-refractory or -dependent acute and chronic GVHD. Between July 2000 and May 2006, 10 patients with aGVHD and 17 with cGVHD were treated with MTX at a dose of 3-10 mg/m(2) weekly....

journal_title：Bone marrow transplantation

authors： Inagaki J,Nagatoshi Y,Hatano M,Isomura N,Sakiyama M,Okamura J

更新日期：2008-03-01 00:00:00

abstract：:Changes in body composition related to metabolic syndrome are frequent among survivors of haematopoietic stem cell transplantation (HSCT), but insights into predisposing factors are incomplete, and it is unknown to what degree these changes persist at long term. We cross-sectionally investigated body composition by du...

journal_title：Bone marrow transplantation

authors： Mejdahl Nielsen M,Mathiesen S,Suominen A,Sørensen K,Ifversen M,Mølgaard C,Lähteenmäki PM,Juul A,Jahnukainen K,Müller K

更新日期：2020-09-02 00:00:00

abstract：:Acute decompensating cardiomyopathy induced by cyclophosphamide is usually irreversible. To investigate the clinical course and the outcome of therapy, 13 patients (1.7%) with grade III acute cardiomyopathy and hypotension who were treated with ablative transplant regimens between January 1980 and September 1995 were ...

journal_title：Bone marrow transplantation

authors： Lee CK,Harman GS,Hohl RJ,Gingrich RD

更新日期：1996-09-01 00:00:00

abstract：:The impact of rhinovirus in hematopoietic SCT (HSCT) recipients is not well defined. A retrospective, matched, case-control study of HSCT recipients with rhinovirus was conducted between 2009 and 2011. Controls were matched for timing relative to transplant, malignancy, and stem cell source. There were 47 cases and 94...

journal_title：Bone marrow transplantation

authors： Abandeh FI,Lustberg M,Devine S,Elder P,Andritsos L,Martin SI

更新日期：2013-11-01 00:00:00

abstract：:Preparative regimens without total body irradiation (TBI) have been reported for alternative donor hemopoietic stem cell transplants (HSCT). Between 7 September 1994 and 7 June 1999 48 patients with advanced hematologic malignancies were conditioned with thiotepa (THIO) 15 mg/kg, cyclophosphamide (CY) 150 mg/kg and an...

journal_title：Bone marrow transplantation

authors： Lamparelli T,van Lint MT,Gualandi F,Raiola AM,Barbanti M,Sacchi N,Ficai G,Ghinatti C,Bregante S,Berisso G,Dominietto A,Di Grazia C,Bruno B,Sessarego M,Casarino L,Verdiani S,Bacigalupo A

更新日期：2000-12-01 00:00:00

abstract：:Following engraftment of donor hematopoietic cells and induction of host-versus-graft tolerance, immunocompetent lymphocytes of donor origin can induce graft-versus-leukemia (GVL) and graft-versus-tumor (GVT) effects. Engraftment of allogeneic bone marrow cells can be accomplished following non-myeloablative condition...

journal_title：Bone marrow transplantation

authors： Slavin S,Or R,Prighozina T,Gurevitch O,Aker M,Panighari S,Shapira M,Nagler A

更新日期：2000-05-01 00:00:00

abstract：:Twenty eight Hungarian patients lacking a compatible related donor and their 61 HLA-A,B,DR serologically identical potential unrelated donors (selected from BMDW) were investigated in this study. Out of the 61 donor-recipient pairs only 7 (11,5%) proved to be HLA-identical at DNA level. Thirty one pairs (50,8%) differ...

journal_title：Bone marrow transplantation

authors： Pénzes M,Rajczy K,Gyódi E,Petrányi GG

更新日期：1998-12-01 00:00:00

abstract：:Acute graft-versus-host disease (GVHD) is the most important complication of allogeneic bone marrow transplantation. We investigated the possibility of predicting severe acute GVHD using plasma interleukin-10 levels in 31 patients who underwent allogeneic bone marrow transplantation. In patients with acute GVHD, the i...

journal_title：Bone marrow transplantation

authors： Takatsuka H,Takemoto Y,Okamoto T,Fujimori Y,Tamura S,Wada H,Okada M,Yamada S,Kanamaru A,Kakishita E

更新日期：1999-11-01 00:00:00

abstract：:Bone marrow (BM) histiocystosis in association with the administration of granulocyte-macrophage colony-stimulating factor (GM-CSF) is a rare phenomenon with few published cases. We report two cases of BM histiocystosis in patients with Hodgkin's disease treated with GM-CSF after autologous bone marrow transplantation...

journal_title：Bone marrow transplantation

authors： Al-Homaidhi A,Prince HM,Al-Zahrani H,Doucette D,Keating A

更新日期：1998-01-01 00:00:00

abstract：:Transplantation of growth factor-mobilized peripheral blood progenitor cells (PBPC) is widely used in the treatment of several neoplastic diseases. While in PBPC harvests the presence of several accessory immune and tumor cells has been documented, that of stromal cells has not been reported. In the present study, we ...

journal_title：Bone marrow transplantation

authors： Fernández M,Simon V,Herrera G,Cao C,Del Favero H,Minguell JJ

更新日期：1997-08-01 00:00:00

abstract：:A double-blind double-dummy, comparative study was carried out in 30 patients receiving highly emetogenic fast dose rate, single fraction total body irradiation prior to bone marrow transplantation. Patients were randomised into one of two groups, receiving either granisetron, a specific 5-HT3 antagonist or a combinat...

journal_title：Bone marrow transplantation

authors： Prentice HG,Cunningham S,Gandhi L,Cunningham J,Collis C,Hamon MD

更新日期：1995-03-01 00:00:00

abstract：:Severe veno-occlusive (VOD) disease is a major cause of morbidity and mortality in allogeneic bone marrow transplant recipients, and new approaches in managing patients who develop serious VOD is needed. In this report, we describe a patient who underwent transjugular intrahepatic portosystemic stent-shunt (TIPS) for ...

journal_title：Bone marrow transplantation

authors： Lévy V,Azoulay D,Rio B,Vincent F,Rabbat A,Hunault M,Bazarbachi A,Delmer A,Zittoun R

更新日期：1996-08-01 00:00:00

abstract：:Omenn syndrome is a variant of SCID, inherited as an autosomal recessive disorder, and characterized by severe eczematoid dermatitis, eosinophilia, elevated serum IgE and a distinctive histology in enlarged lymph nodes. The etiology of Omenn syndrome is unknown, however, unlike other forms of SCID; patients with Omenn...

journal_title：Bone marrow transplantation

authors： Loechelt BJ,Shapiro RS,Jyonouchi H,Filipovich AH

更新日期：1995-09-01 00:00:00

abstract：:POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) is a plasma cell dyscrasia that differs substantially from classic multiple myeloma. It is often associated with disabling polyneuropathy in younger patients. Current therapeutic approaches are frequently inadequate ...

journal_title：Bone marrow transplantation

authors： Hogan WJ,Lacy MQ,Wiseman GA,Fealey RD,Dispenzieri A,Gertz MA

更新日期：2001-08-01 00:00:00

abstract：:Minimal residual disease (MRD) monitoring via quantitative PCR (qPCR) detection of Ag receptor gene rearrangements has been the most sensitive method for predicting prognosis and making post-transplant treatment decisions for patients with ALL. Despite the broad clinical usefulness and standardization of this method, ...

journal_title：Bone marrow transplantation

authors： Kotrova M,van der Velden VHJ,van Dongen JJM,Formankova R,Sedlacek P,Brüggemann M,Zuna J,Stary J,Trka J,Fronkova E

更新日期：2017-07-01 00:00:00

abstract：:Recent reports have suggested that the total number of autologous or allogeneic hematopoietic stem cell (HSC) infused after high-dose chemotherapy might predict survival, post-transplant morbidity and rate of hematopoietic engraftment. However, HSC capable of long-term multilineage potential are still poorly defined, ...

journal_title：Bone marrow transplantation

authors： Bertolini F,Battaglia M,Lanza A,Gibelli N,Palermo B,Pavesi L,Robustelli della Cuna G

更新日期：1998-07-01 00:00:00

abstract：:Syngeneic BMT was first performed successfully in China in 1964. In 1981, allogeneic BMT was applied in an acute leukemia patient with success. Since then, the number of BMTs has been increasing gradually, especially since the 1990s. More than 2000 stem cell transplants per year have been performed in recent years in ...

journal_title：Bone marrow transplantation

authors： Wu T,Lu DP

更新日期：2008-08-01 00:00:00